Research programme: antibody-drug conjugate therapeutics - CytomX Therapeutics/AbbVie

Drug Profile

Research programme: antibody-drug conjugate therapeutics - CytomX Therapeutics/AbbVie

Alternative Names: CD71 PDC; CX 2029

Latest Information Update: 12 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CytomX Therapeutics
  • Class Antineoplastics; Immunoconjugates
  • Mechanism of Action CD71 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Jun 2017 CytomX therapeutics plans file an IND application in USA for Cancer
  • 12 Jan 2017 Preclinical trials in Cancer in USA (unspecified route)
  • 21 Apr 2016 AbbVie and CytomX agree to co-develop Probody-drug conjugates for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top